pre-IPO PHARMA

COMPANY OVERVIEW

Amorsa is a neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders including treatment-resistant depression, bipolar disorder, PTSD and moderate-to-severe pain. Founded in 2013, Amorsa has assembled a leadership team with experience in building several successful life science companies and a strong track record in developing novel therapeutic treatments. In addition, Amorsa has attracted leading neuroscience and pain management experts to join its Scientific and Clinical Advisory Board.


LOCATION

  • Southborough, MA, USA

  • THERAPEUTIC AREAS

  • Neurological Disorders
  • Pain

  • WEBSITE

    https://www.amorsatx.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Feb 14, 2019

    Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Deuterated Norketamine and Related Compounds


    Jun 1, 2018

    Amorsa Therapeutics Appoints Jeffrey Wiesen to Board of Directors


    Jan 9, 2018

    Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Oral Compositions of Ketamine and Related Compounds


    Jan 5, 2017

    Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson and Johnson Innovation to Develop New Therapy for Treatment-Resistant Depression


    Feb 1, 2016

    Amorsa Therapeutics Selected to Present at Cavendish Global Health Impact Forum


    For More Press Releases


    Google Analytics Alternative